Eton Pharmaceuticals, Inc. Fair Value Adjustment of Warrants
Eton Pharmaceuticals, Inc. (ETON) reported Fair Value Adjustment of Warrants of $2.58 million for the 12-month period ending 2018-12-31, per its 10-K filed 2021-03-16.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2021-03-16
- Eton Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2018-12-31 was $1.53M.
- Eton Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2018-09-30 was $561.00K, a 1268.29% increase year-over-year.
- Eton Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2018-06-30 was $413.00K.
- Eton Pharmaceuticals, Inc. fair value adjustment of warrants for the quarter ending 2018-03-31 was $83.00K.
- Eton Pharmaceuticals, Inc. fair value adjustment of warrants for fiscal 2018 was $2.58M.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 5 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 8 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|---|---|
| 2018-12-31 | $1.53M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | $2.09M derived: sum of 2 quarters · filed 2021-03-16 | $2.50M derived: sum of 3 quarters · filed 2021-03-16 | $2.58M 10-K · filed 2021-03-16 | ||
| 2018-09-30 | $561.00K 10-Q · filed 2019-11-14 | $974.00K derived: sum of 2 quarters · filed 2019-11-14 | $1.06M 10-Q · filed 2019-11-14 | |||
| 2018-06-30 | $413.00K 10-Q · filed 2019-08-06 | $496.00K 10-Q · filed 2019-08-06 | ||||
| 2018-03-31 | $83.00K 10-Q · filed 2019-05-07 | |||||
| 2017-12-31 | $41.00K 10-K · filed 2020-03-05 | |||||
| 2017-09-30 | $41.00K 10-Q · filed 2018-12-20 | $41.00K 10-Q · filed 2018-12-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |